Evidence map›Paper›PMID 32072136›Full record

ArticleHemaSphere2020

Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study.

Lucia Morello, Sara Rattotti, Laura Giordano, Mats Jerkeman, Tom van Meerten, Katarzyna Krawczyk, Filipa Moita, Dario Marino, Simone Ferrero, Michał Szymczyk and 10 more

Open access · goldAbstract read
In one paragraph

Article in HemaSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 7 countries.

Lucia MorelloDepartment of Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Italy.
Sara RattottiDivision of Hematology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
Laura GiordanoBiostatistic Unit, Humanitas Clinical and Research Center, Rozzano, Italy.
Mats JerkemanDepartment of Oncology, Skane University Hospital, SE-221 85 Lund, Sweden.
Tom van MeertenDepartment of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
Katarzyna KrawczykDepartment of Hematology, Jagiellonian University, Kraków, Poland.
Filipa MoitaInstituto Português de Oncologia de Lisboa de Francisco Gentil, Lisbon, Portugal.
Dario MarinoOncology Unit 1 Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Simone FerreroDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy.
Michał SzymczykDepartment of Lymphoid Malignancies, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Igor AurerDivision of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Croatia.
Tarec Christoffer El-GalalyDepartment of Hematology, Aalborg University Hospital, Denmark.
Alice Di RoccoDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
Carlo ViscoDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Giuseppe CarliDepartment of Cell Therapy and Haematology, San Bortolo Hospital, Vicenza, Italy.
Irene DefrancescoDivision of Hematology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
Carmelo Carlo-StellaDepartment of Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Italy.
Martin DreylingDepartment of Medicine III, University Hospital LMU, Munich, Germany.
Armando SantoroDepartment of Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Italy.
Luca ArcainiDivision of Hematology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
Humanitas University · ITIstituto Oncologico Veneto · ITPoliclinico San Matteo Fondazione · ITSkåne University Hospital · SEIstituti di Ricovero e Cura a Carattere Scientifico · ITJagiellonian University · PLLudwig-Maximilians-Universität München · DESapienza University of Rome · ITThe Maria Sklodowska-Curie National Research Institute of Oncology · PLUniversity Hospital Centre Zagreb · HRUniversity Medical Center Groningen · NLUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While classical nodal mantle cell lymphoma (cMCL) is often associated with involvement of multiple extranodal sites, isolated extranodal disease (ED) at the time of diagnosis is a rare event; data on the outcome of these forms are lacking. On behalf of the European MCL Network, we conducted a retrospective analysis on the clinical characteristics and outcomes of MCL presenting with isolated or predominant ED (MALT MCL). We collected data on 127 patients with MALT MCL diagnosed from 1998 to 2015: 78 patients (61%) were male with a median age of 65 years. The involved sites include: upper airways + Waldeyer ring (40; 32%), gastrointestinal tract (32; 25%), ocular adnexa (17; 13%), oral cavity and salivary glands (17; 13%) and others (13; 1%); 7 patients showed multiple extranodal sites. The median follow-up was 80 months (range: 6-182), 5-year progression-free survival (PFS) was 45% (95% CI: 35-54) and 5-year overall survival (OS) was 71% (95% CI: 62-79). In an explorative setting, we compared MALT MCL with a group of 128 cMCL patients: MALT MCL patients showed a significantly longer PFS and OS compared with nodal cMCL; with a median PFS of 4.5 years vs 2.8 years (p = 0.001) and median OS of 9.8 years vs 6.9 years (p = 0.018), respectively. Patients with MALT MCL at diagnosis showed a more favorable prognosis and indolent course than classical nodal type. This clinical variant of MCL should be acknowledged to avoid possible over-treatment.

Identifiers

PMID32072136
PMCPMC7000480
OpenAlexW3000195978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.